Digoxin

( DrugBank: Digoxin / KEGG DRUG: Digoxin )

3 diseases

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	1
46	Malignant rheumatoid arthritis	5

ID	Disease name (Link within this page)	Number of trials
210	Single Ventricle	1

8. Huntington disease

Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00831506 (ClinicalTrials.gov)	February 2009	27/1/2009	Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Ste ...	Alzheimer Disease;Huntington Disease	Drug: digoxin;Drug: dimebon	Pfizer	Medivation, Inc.	Completed	18 Years	55 Years	Both	12	Phase 1	United States

First Previous1Next Last

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

trials per page:

Showing 1 to 5 of 5 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04834557 (ClinicalTrials.gov)	November 1, 2021	2/4/2021	Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis	Evaluating the Effect of Digoxinand Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis in Eg ...	Rheumatoid Arthritis	Drug: Placebo;Drug: Digoxin 0.25 mg;Drug: Ursodeoxycholic acid (UDCA) 500 mg	Tanta University	NULL	Recruiting	18 Years	80 Years	All	90	Phase 2	Egypt
2	NCT03131973 (ClinicalTrials.gov)	May 13, 2017	25/4/2017	Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbipr ...	Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrex ...	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbipr ...	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	All	26	Phase 1	United States
3	NCT02762123 (ClinicalTrials.gov)	May 2016	3/5/2016	A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates	Effects of Concomitant Administration of BMS-986142 on the Single-dose Pharmacokinetics of Probe Sub ...	Rheumatoid Arthritis	Drug: BMS-986142 200mg;Drug: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazo ...	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	Both	28	Phase 1	United States
4	NCT02456844 (ClinicalTrials.gov)	May 2015	27/5/2015	Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe ...	Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Monte ...	Rheumatoid Arthritis	Drug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142;Drug: Methotrexate, ...	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	Both	24	Phase 1	NULL
5	NCT01355354 (ClinicalTrials.gov)	June 2011	17/5/2011	Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects	An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digox ...	Healthy Volunteers;Rheumatoid Arthritis	Drug: Digoxin;Drug: Fostamatinib	AstraZeneca	NULL	Completed	18 Years	45 Years	Both	21	Phase 1	United Kingdom

First Previous1Next Last

210. Single Ventricle

Clinical trials : 51 / Drugs : 53 - (DrugBank : 22) / Drug target genes : 32 - Drug target pathways : 67

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03877965 (ClinicalTrials.gov)	August 5, 2019	14/3/2019	Pharmacokinetics and Safety Profile of Digoxinin Infants With Single Ventricle Congenital Heart Dise ...	Pharmacokinetics and Safety Profile of Digoxinin Infants With Single Ventricle Congenital Heart Dise ...	Congenital Heart Disease	Drug: Digoxin	Christoph P Hornik, MD MPH	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);The Emmes Co ...	Completed	N/A	6 Months	All	50		United States

First Previous1Next Last